OncoMatch/Clinical Trials/NCT06356688
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Is NCT06356688 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Paclitaxel Polymeric Micelles for for locally advanced esophageal squamous cell carcinoma.
Treatment: Paclitaxel Polymeric Micelles for — The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT2-4AN+, CT3-4AN0, II, III, IVA (AJCC 8th edition cTNM)
Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable...clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: radiotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: immunotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: surgery
Patients who have previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.)
Lab requirements
Blood counts
WBC ≥3×10^9/L, ANC ≥1.5×10^9/L, PLT ≥100×10^9/L, Hb ≥9g/dL
Kidney function
cCr>40 ml/min, Cr≤1.5 ULN
Liver function
TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN
Cardiac function
no cardiac disease or coronary artery disease, cardiac function grade 1-2
Adequate baseline organ function: (i) WBC ≥3×10^9/L, ANC ≥1.5×10^9/L, PLT ≥100×10^9/L, Hb ≥9g/dL; (ii) Liver function: TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN; (iii) Renal function: cCr>40 ml/min, Cr≤1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify